Market Dynamics

Changing lifestyle pattern, increase in number of patients suffering from neurological disorder is resulting in demand for advanced treatment this is major factor expected to drive the growth of global cluster headache syndrome market. A cluster headache is a relatively rare type of headache that affects less than 0.5% of the population. Consumers approach towards adoption of advanced treatment in order to cure the disorder is resulting in introduction of advance medical device and solution from players is gaining traction. High spending on healthcare is also attracting player’s interest. According to U.S. Department of Health & Human Services, Per capita national health expenditure was US$ 11,172 in 2018. Percent of national health expenditures for physician and clinical services was 19.9% in 2018. In total, the economic impact of migraine headache in the United States is estimated to be between US$13 and US$17 billion annually. Increasing R&D activities by major players for development of novel products and supporting government regulations are factors expected to boost the growth of cluster headache syndrome market.

In 2019, U.S. Food and Drug Administration approved “Emgality” for the treatment of episodic cluster headache in adults presented by Eli Lilly Company. The effectiveness of Emgality for the treatment of episodic cluster headache was demonstrated in a clinical trial that compared the drug to placebo in 106 patients.

In 2017, the U.S. Food and Drug Administration approved a noninvasive device medical device manufactured by electroCore called “gammaCore” a hand-held device to treat Cluster headaches. GammaCore was based on two clinical trials that found the device was more effective than placebo in reducing cluster headache pain.

High spending by the government of developing countries on development of present infrastructure and focus on development new therapies such as monoclonal antibody are factors expected to augment the growth of cluster headache syndrome market. Players focus towards R&D activities and development of new drugs with help of monoclonal antibody. The drug blocks calcitonin gene related peptide ligand that modulates nociceptive trigeminal neurons involved in the pathophysiology of cluster headaches. Factors such as high cost of associated to R&D activities and stringent regulatory scenario are expected to hamper the growth of global cluster headache syndrome market. In addition, lack of awareness among patients and less developed infrastructure for R&D activities is expected to challenge the growth of target market. However, high funding by major players, increasing clinical trials for development of new drugs and devices and increasing awareness activities by the government are factors expected to create new opportunities or players operating in the cluster headache syndrome market over the forecast period. In addition, increasing spending on development of healthcare sector and increasing partnership between regional and international players is expected to support the revenue transaction of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global cluster headache syndrome market due to large number of people suffering from neurological problems. Presence of large number of players operating in the county, increasing R&D activities and introduction of new solutions are factors expected to support the growth of target market. In addition, increasing merger & acquisition activities in order to enhance the customer base and increase the revenue share are factors expected to support the growth of cluster headache syndrome market.

Competitive Landscape      

The global cluster headache syndrome market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Cluster Headache Syndrome Market Segment Analysis, 2019

The global cluster headache syndrome market is segmented into type, drug and distribution channel. The drug type segment is divided in to calcium channel blockers, corticosteroids, sumatriptan, lithium carbonate, ergots, melatonin, anti-seizure, and local anesthetics. The distribution channel segment is bifurcated into hospitals clinics, private clinics, retail pharmacies and drug stores, and e-commerce. Among distribution channel the e-commerce segment is expected to witness faster growth in the cluster headache syndrome market. The players profiled in the report are GlaxoSmithKline plc, Eli Lilly and Co, AstraZeneca, ElectroCore Medical LLC, Autonomic Technologies, TrioxBio Inc, Center Laboratories Inc, Crossject SA, Novartis AG, Teva Pharmaceutical Industries Ltd, and Winston Pharmaceuticals.

Market Segmentation

Market By Type

Episodic
Chronic

Market By Drug Type

Calcium channel blockers
Corticosteroids
Sumatriptan
Lithium carbonate
Ergots
Melatonin
Anti-seizure
Local anesthetics

Market By Distribution Channel

Hospitals Clinics
Private Clinics
Retail Pharmacies and Drug Stores
E-commerce

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa